^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Undisclosed mDC3/8-KRAS vaccine

    i
    Other names: Undisclosed mDC3/8-KRAS vaccine
    Associations

    News

    Trials
    Company:
    University of Pennsylvania
    Drug class:
    Immunostimulant, KRAS inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    DC Vaccine in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, University of Pennsylvania | N=12 --> 29
    Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11
    |
    Undisclosed mDC3/8-KRAS vaccine
    6ms
    DC Vaccine in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11
    |
    Undisclosed mDC3/8-KRAS vaccine
    7ms
    DC Vaccine in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Pennsylvania | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02
    |
    Undisclosed mDC3/8-KRAS vaccine
    1year
    DC Vaccine in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Pennsylvania | Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02
    |
    Undisclosed mDC3/8-KRAS vaccine
    over1year
    DC Vaccine in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=12, Recruiting, University of Pennsylvania | Trial completion date: Sep 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02
    |
    Undisclosed mDC3/8-KRAS vaccine